BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer

Trial Profile

BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab; Capecitabine
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms BACCI
  • Most Recent Events

    • 24 Mar 2017 Planned initiation date changed from 1 Mar 2017 to 1 Apr 2017.
    • 24 Jan 2017 Planned initiation date changed from 1 Oct 2016 to 1 Mar 2017.
    • 26 Sep 2016 Planned initiation date changed from 1 Aug 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top